Aytu BioPharma appoints Christopher Brooke as COO, effective Nov 14, 2022

AYTU BIOPHARMA, INC

Christopher Brooke previously served as EVP Rare Disease Development since April 2021.
Brooke holds a 47.5% ownership interest in Rumpus, from which Aytu acquired enzastaurin license.
Aytu paid $4.0M in milestones to Rumpus in fiscal 2022 ($2.6M cash + 2,188,940 shares).
Brooke has over 20 years healthcare management experience at Johnson & Johnson, AstraZeneca, and AmerisourceBergen.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher Brooke

Chief Operating Officer

AYTU · AYTU BIOPHARMA, INC

Effective: 2022-11-14
Filed: November 15, 2022, 6:59 PM ET

Effective November 14, 2022, Aytu BioPharma, Inc. (the “Company”) appointed Christopher Brooke as Chief Operating Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Christopher Brooke was appointed as Chief Operating Officer at AYTU BIOPHARMA, INC.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

Effective November 14, 2022, Aytu BioPharma, Inc. (the “Company”) appointed Christopher Brooke as Chief Operating Officer

View on SEC.gov

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-22-017922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.